Erratum: Stojkovic et al IL-33 stimulates the release of procoagulant microvesicles from human monocytes and differentially increases tissue factor in human monocyte subsets (Thromb Haemost (2014) 111 (670-678) DOI: 10.1160/TH16-10-0784);IL-33 stimulates the release of procoagulant microvesicles from human monocytes and differentially increases tissue factor in human monocyte subsets

Thrombosis and Haemostasis

Volumn 117, Issue 7, 2017, Pages 1379-1390

  Stojkovic, Stefan ^a   Thulin, Åsa ^b   Hell, Lena ^a   Thaler, Barbara ^a   Rauscher, Sabine ^a   Baumgartner, Johanna ^a   Gröger, Marion ^a   Ay, Cihan ^a   Demyanets, Svitlana ^a   Neumayer, Christoph ^a   Huk, Ihor ^a   Spittler, Andreas ^a   Huber, Kurt ^a,c   Wojta, Johann ^a,d   Siegbahn, Agneta ^b   Åberg, Mikael ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UPPSALA UNIVERSITY   (Sweden)

^c WILHELMINEN HOSPITAL   (Austria)

^d Ludwig Boltzmann Cluster for Cardiovascular Research   (Austria)

Author keywords

Interleukin 33; Microvesicles; Monocyte subsets; Thrombosis; Tissue factor

Indexed keywords

CD14 ANTIGEN; CD16 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; INTERLEUKIN 33; MESSENGER RNA; NUCLEAR PROTEIN; PROCOAGULANT; PROTEIN; THROMBOPLASTIN; IL1RL1 PROTEIN, HUMAN; IL33 PROTEIN, HUMAN; LIPOPOLYSACCHARIDE RECEPTOR; RECOMBINANT PROTEIN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CAROTID ARTERY OBSTRUCTION; CELL SELECTION; CLINICAL ARTICLE; CONFOCAL LASER SCANNING MICROSCOPY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; MALE; MEMBRANE MICROPARTICLE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; BLOOD; CELL CULTURE; CLASSIFICATION; GENETICS; IMMUNOLOGY; MIDDLE AGED; PHYSIOLOGY; SECRETION (PROCESS); THROMBOSIS;

AGED; CAROTID STENOSIS; CELL-DERIVED MICROPARTICLES; CELLS, CULTURED; FEMALE; HUMANS; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; INTERLEUKIN-33; LIPOPOLYSACCHARIDE RECEPTORS; MALE; MIDDLE AGED; MONOCYTES; NF-KAPPA B; RECOMBINANT PROTEINS; RNA, MESSENGER; THROMBOPLASTIN; THROMBOSIS;

EID: 85021685044     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH1710001     Document Type: Erratum

References (50)

1. Aberg M, Eriksson O, Siegbahn A. Tissue Factor Noncoagulant Signaling: Mechanisms and Implications for Cell Migration and Apoptosis. Semin Thromb Hemost 2015; 41: 691-699.
2. Wilcox JN, Smith KM, Schwartz SM, et al. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-2843.
3. Giesen PL, Rauch U, Bohrmann B, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311-2315.
4. Brambilla M, Facchinetti L, Canzano P, et al. Human megakaryocytes confer tissue factor to a subset of shed platelets to stimulate thrombin generation. Thromb Haemost 2015; 114: 579-592.
5. Ernofsson M, Siegbahn A. Platelet-derived growth factor-BB and monocyte chemotactic protein-1 induce human peripheral blood monocytes to express tissue factor. Thromb Res 1996; 83: 307-320.
6. Lindmark E, Tenno T, Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol 2000; 20: 2322-2328.
7. Mackman N. Regulation of the tissue factor gene. FASEB J 1995; 9: 883-889.
8. Breitenstein A, Tanner FC, Luscher TF. Tissue factor and cardiovascular disease: quo vadis? Circ J 2010; 74: 3-12.
9. Hron G, Kollars M, Weber H, et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007; 97: 119-123.
10. Leatham EW, Bath PM, Tooze JA, et al. Increased monocyte tissue factor expression in coronary disease. Br Heart J 1995; 73: 10-13.
11. Kakkar AK, DeRuvo N, Chinswangwatanakul V, et al. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995; 346: 1004-1005.
12. Holschermann H, Haberbosch W, Terhalle HM, et al. Increased monocyte tissue factor activity in women following cerebral venous thrombosis. J Neurol 2003; 250: 631-632.
13. Matsumoto N, Nomura S, Kamihata H, et al. Increased level of oxidized LDLdependent monocyte-derived microparticles in acute coronary syndrome. Thromb Haemost 2004; 91: 146-154.
14. Khorana AA, Francis CW, Menzies KE, et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 2008; 6: 1983-1985.
15. Geddings JE, Mackman N. New players in haemostasis and thrombosis. Thromb Haemost 2014; 111: 570-574.
16. Pawlinski R, Mackman N. Cellular sources of tissue factor in endotoxemia and sepsis. Thromb Res 2010; 125 (Suppl 1): S70-73.
17. Ruf W. Tissue factor and cancer. Thromb Res 2012; 130 (Suppl 1): S84-87.
18. Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010; 116: e74-80.
19. Weber C, Shantsila E, Hristov M, et al. Role and analysis of monocyte subsets in cardiovascular disease. Joint consensus document of the European Society of Cardiology (ESC) Working Groups „Atherosclerosis & Vascular Biology“and „Thrombosis“. Thromb Haemost 2016; 116: 626-637.
20. Wong KL, Tai JJ, Wong WC, et al. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood 2011; 118: e16-31.
21. Cros J, Cagnard N, Woollard K, et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 2010; 33: 375-386.
22. Mukherjee R, Kanti Barman P, Kumar Thatoi P, et al. Non-Classical monocytes display inflammatory features: Validation in Sepsis and Systemic Lupus Erythematous. Sci Rep 2015; 5: 13886.
23. Leers MP, Keuren JF, Frissen ME, et al. The pro-and anticoagulant role of blood-borne phagocytes in patients with acute coronary syndrome. Thromb Haemost 2013; 110: 101-109.
24. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23: 479-490.
25. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010; 10: 103-110.
26. Kakkar R, Hei H, Dobner S, et al. Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J Biol Chem 2012; 287: 6941-6948.
27. Miller AM. Role of IL-33 in inflammation and disease. J Inflamm 2011; 8: 22.
28. Stojkovic S, Kaun C, Heinz M, et al. Interleukin-33 induces urokinase in human endothelial cells-possible impact on angiogenesis. J Thromb Haemost 2014; 12: 948-957.
29. Demyanets S, Konya V, Kastl SP, et al. Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2011; 31: 2080-2089.
30. Stojkovic S, Kaun C, Basilio J, et al. Tissue factor is induced by interleukin-33 in human endothelial cells: a new link between coagulation and inflammation. Sci Rep 2016; 6: 25171.
31. Aoki S, Hayakawa M, Ozaki H, et al. ST2 gene expression is proliferation-dependent and its ligand, IL-33, induces inflammatory reaction in endothelial cells. Mol Cell Biochem 2010; 335: 75-81.
32. Montanari E, Stojkovic S, Kaun C, et al. Interleukin-33 stimulates GM-CSF and M-CSF production by human endothelial cells. Thromb Haemost 2016; 116: 317-327.
33. Choi YS, Choi HJ, Min JK, et al. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood 2009; 114: 3117-3126.
34. Demyanets S, Speidl WS, Tentzeris I, et al. Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome. PLoS One 2014; 9: e95055.
35. Dhillon OS, Narayan HK, Khan SQ, et al. Pre-discharge risk stratification in unselected STEMI: is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers? Int J Cardiol 2013; 167: 2182-2188.
36. Demyanets S, Kaun C, Pentz R, et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J Mol Cell Cardiol 2013; 60: 16-26.
37. Abeles RD, McPhail MJ, Sowter D, et al. CD14, CD16 and HLA-DR reliably identifies human monocytes and their subsets in the context of pathologically reduced HLA-DR expression by CD14(hi) /CD16(neg) monocytes: Expansion of CD14(hi) /CD16(pos) and contraction of CD14(lo) /CD16(pos) monocytes in acute liver failure. Cytometry A 2012; 81: 823-834.
38. North American Symptomatic Carotid Endarterectomy Trial. Methods, patient characteristics, and progress. Stroke 1991; 22: 711-720.
39. Christersson C, Johnell M, Siegbahn A. Evaluation of microparticles in whole blood by multicolour flow cytometry assay. Scand J Clin Lab Invest 2013; 73: 229-239.
40. Mun SH, Ko NY, Kim HS, et al. Interleukin-33 stimulates formation of functional osteoclasts from human CD14(+) monocytes. Cell Mol Life Sci 2010; 67: 3883-392.
41. Ghattas A, Griffiths HR, Devitt A, et al. Monocytes in coronary artery disease and atherosclerosis: where are we now? J Am Coll Cardiol 2013; 62: 1541-1551.
42. Krychtiuk KA, Kastl SP, Speidl WS, et al. Inflammation and coagulation in atherosclerosis. Hamostaseologie 2013; 33: 269-282.
43. Mallat Z, Benamer H, Hugel B, et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101: 841-843.
44. Schlitt A, Heine GH, Blankenberg S, et al. CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. Thromb Haemost 2004; 92: 419-424.
45. Rogacev KS, Cremers B, Zawada AM, et al. CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol 2012; 60: 1512-1520.
46. Guha M, O’Connell MA, Pawlinski R, et al. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood 2001; 98: 1429-1439.
47. Koga H, Sugiyama S, Kugiyama K, et al. Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2005; 45: 1622-1630.
48. Leroyer AS, Isobe H, Leseche G, et al. Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. J Am Coll Cardiol 2007; 49: 772-777.
49. Miller AM, Xu D, Asquith DL, et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008; 205: 339-346.
50. Martin P, Palmer G, Rodriguez E, et al. Atherosclerosis severity is not affected by a deficiency in IL-33/ST2 signaling. Immun Inflamm Dis 2015; 3: 239-246.